Kristin K Nicodemus1,2, April Hargreaves1, Derek Morris1, Richard Anney1, Michael Gill1, Aiden Corvin1, Gary Donohoe1,3. 1. Neuropsychiatric Genetics Group, Department of Psychiatry, Trinity College Dublin, St. James Hospital, Dublin 8, Ireland. 2. Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, UK. 3. School of Psychology, National University of Ireland Galway, University Road, Galway, Ireland.
Abstract
IMPORTANCE: We investigated the variation in neuropsychological function explained by risk alleles at the psychosis susceptibility gene ZNF804A and its interacting partners using single nucleotide polymorphisms (SNPs), polygenic scores, and epistatic analyses. Of particular importance was the relative contribution of the polygenic score vs epistasis in variation explained. OBJECTIVES: To (1) assess the association between SNPs in ZNF804A and the ZNF804A polygenic score with measures of cognition in cases with psychosis and (2) assess whether epistasis within the ZNF804A pathway could explain additional variation above and beyond that explained by the polygenic score. DESIGN, SETTING, AND PARTICIPANTS: Patients with psychosis (n = 424) were assessed in areas of cognitive ability impaired in schizophrenia including IQ, memory, attention, and social cognition. We used the Psychiatric GWAS Consortium 1 schizophrenia genome-wide association study to calculate a polygenic score based on identified risk variants within this genetic pathway. Cognitive measures significantly associated with the polygenic score were tested for an epistatic component using a training set (n = 170), which was used to develop linear regression models containing the polygenic score and 2-SNP interactions. The best-fitting models were tested for replication in 2 independent test sets of cases: (1) 170 individuals with schizophrenia or schizoaffective disorder and (2) 84 patients with broad psychosis (including bipolar disorder, major depressive disorder, and other psychosis). MAIN OUTCOMES AND MEASURES: Participants completed a neuropsychological assessment battery designed to target the cognitive deficits of schizophrenia including general cognitive function, episodic memory, working memory, attentional control, and social cognition. RESULTS: Higher polygenic scores were associated with poorer performance among patients on IQ, memory, and social cognition, explaining 1% to 3% of variation on these scores (range, P = .01 to .03). Using a narrow psychosis training set and independent test sets of narrow phenotype psychosis (schizophrenia and schizoaffective disorder), broad psychosis, and control participants (n = 89), the addition of 2 interaction terms containing 2 SNPs each increased the R2 for spatial working memory strategy in the independent psychosis test sets from 1.2% using the polygenic score only to 4.8% (P = .11 and .001, respectively) but did not explain additional variation in control participants. CONCLUSIONS AND RELEVANCE: These data support a role for the ZNF804A pathway in IQ, memory, and social cognition in cases. Furthermore, we showed that epistasis increases the variation explained above the contribution of the polygenic score.
IMPORTANCE: We investigated the variation in neuropsychological function explained by risk alleles at the psychosis susceptibility gene ZNF804A and its interacting partners using single nucleotide polymorphisms (SNPs), polygenic scores, and epistatic analyses. Of particular importance was the relative contribution of the polygenic score vs epistasis in variation explained. OBJECTIVES: To (1) assess the association between SNPs in ZNF804A and the ZNF804A polygenic score with measures of cognition in cases with psychosis and (2) assess whether epistasis within the ZNF804A pathway could explain additional variation above and beyond that explained by the polygenic score. DESIGN, SETTING, AND PARTICIPANTS: Patients with psychosis (n = 424) were assessed in areas of cognitive ability impaired in schizophrenia including IQ, memory, attention, and social cognition. We used the Psychiatric GWAS Consortium 1 schizophrenia genome-wide association study to calculate a polygenic score based on identified risk variants within this genetic pathway. Cognitive measures significantly associated with the polygenic score were tested for an epistatic component using a training set (n = 170), which was used to develop linear regression models containing the polygenic score and 2-SNP interactions. The best-fitting models were tested for replication in 2 independent test sets of cases: (1) 170 individuals with schizophrenia or schizoaffective disorder and (2) 84 patients with broad psychosis (including bipolar disorder, major depressive disorder, and other psychosis). MAIN OUTCOMES AND MEASURES: Participants completed a neuropsychological assessment battery designed to target the cognitive deficits of schizophrenia including general cognitive function, episodic memory, working memory, attentional control, and social cognition. RESULTS: Higher polygenic scores were associated with poorer performance among patients on IQ, memory, and social cognition, explaining 1% to 3% of variation on these scores (range, P = .01 to .03). Using a narrow psychosis training set and independent test sets of narrow phenotype psychosis (schizophrenia and schizoaffective disorder), broad psychosis, and control participants (n = 89), the addition of 2 interaction terms containing 2 SNPs each increased the R2 for spatial working memory strategy in the independent psychosis test sets from 1.2% using the polygenic score only to 4.8% (P = .11 and .001, respectively) but did not explain additional variation in control participants. CONCLUSIONS AND RELEVANCE: These data support a role for the ZNF804A pathway in IQ, memory, and social cognition in cases. Furthermore, we showed that epistasis increases the variation explained above the contribution of the polygenic score.
Authors: Kristin K Nicodemus; Amanda J Law; Eugenia Radulescu; Augustin Luna; Bhaskar Kolachana; Radhakrishna Vakkalanka; Dan Rujescu; Ina Giegling; Richard E Straub; Kate McGee; Bert Gold; Michael Dean; Pierandrea Muglia; Joseph H Callicott; Hao-Yang Tan; Daniel R Weinberger Journal: Arch Gen Psychiatry Date: 2010-10
Authors: Michael C O'Donovan; Nicholas Craddock; Nadine Norton; Hywel Williams; Timothy Peirce; Valentina Moskvina; Ivan Nikolov; Marian Hamshere; Liam Carroll; Lyudmila Georgieva; Sarah Dwyer; Peter Holmans; Jonathan L Marchini; Chris C A Spencer; Bryan Howie; Hin-Tak Leung; Annette M Hartmann; Hans-Jürgen Möller; Derek W Morris; Yongyong Shi; GuoYin Feng; Per Hoffmann; Peter Propping; Catalina Vasilescu; Wolfgang Maier; Marcella Rietschel; Stanley Zammit; Johannes Schumacher; Emma M Quinn; Thomas G Schulze; Nigel M Williams; Ina Giegling; Nakao Iwata; Masashi Ikeda; Ariel Darvasi; Sagiv Shifman; Lin He; Jubao Duan; Alan R Sanders; Douglas F Levinson; Pablo V Gejman; Sven Cichon; Markus M Nöthen; Michael Gill; Aiden Corvin; Dan Rujescu; George Kirov; Michael J Owen; Nancy G Buccola; Bryan J Mowry; Robert Freedman; Farooq Amin; Donald W Black; Jeremy M Silverman; William F Byerley; C Robert Cloninger Journal: Nat Genet Date: 2008-09 Impact factor: 38.330
Authors: H J Williams; N Norton; S Dwyer; V Moskvina; I Nikolov; L Carroll; L Georgieva; N M Williams; D W Morris; E M Quinn; I Giegling; M Ikeda; J Wood; T Lencz; C Hultman; P Lichtenstein; D Thiselton; B S Maher; A K Malhotra; B Riley; K S Kendler; M Gill; P Sullivan; P Sklar; S Purcell; V L Nimgaonkar; G Kirov; P Holmans; A Corvin; D Rujescu; N Craddock; M J Owen; M C O'Donovan Journal: Mol Psychiatry Date: 2010-04-06 Impact factor: 15.992
Authors: Todd Lencz; Philip R Szeszko; Pamela DeRosse; Katherine E Burdick; Evelyn J Bromet; Robert M Bilder; Anil K Malhotra Journal: Neuropsychopharmacology Date: 2010-07-21 Impact factor: 7.853
Authors: Kristin K Nicodemus; Joseph H Callicott; Rachel G Higier; Augustin Luna; Devon C Nixon; Barbara K Lipska; Radhakrishna Vakkalanka; Ina Giegling; Dan Rujescu; David St Clair; Pierandrea Muglia; Yin Yao Shugart; Daniel R Weinberger Journal: Hum Genet Date: 2010-04 Impact factor: 4.132
Authors: Amanda B Zheutlin; Adam M Chekroud; Renato Polimanti; Joel Gelernter; Fred W Sabb; Robert M Bilder; Nelson Freimer; Edythe D London; Christina M Hultman; Tyrone D Cannon Journal: Schizophr Bull Date: 2018-08-20 Impact factor: 9.306
Authors: Colm M P O'Tuathaigh; Fabio Fumagalli; Lieve Desbonnet; Francesc Perez-Branguli; Gerard Moloney; Samim Loftus; Claire O'Leary; Emilie Petit; Rachel Cox; Orna Tighe; Gerard Clarke; Donna Lai; Richard P Harvey; John F Cryan; Kevin J Mitchell; Timothy G Dinan; Marco A Riva; John L Waddington Journal: Schizophr Bull Date: 2016-09-09 Impact factor: 9.306
Authors: Donna Cosgrove; Omar Mothersill; Kimberley Kendall; Bettina Konte; Denise Harold; Ina Giegling; Annette Hartmann; Alex Richards; Kiran Mantripragada; Michael J Owen; Michael C O'Donovan; Michael Gill; Dan Rujescu; James Walters; Aiden Corvin; Derek W Morris; Gary Donohoe Journal: Neuropsychopharmacology Date: 2017-06-13 Impact factor: 7.853
Authors: Brita Elvevåg; Alex S Cohen; Maria K Wolters; Heather C Whalley; Viktoria-Eleni Gountouna; Ksenia A Kuznetsova; Andrew R Watson; Kristin K Nicodemus Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-03-10 Impact factor: 3.568
Authors: D Cosgrove; D Harold; O Mothersill; R Anney; M J Hill; N J Bray; G Blokland; T Petryshen; A Richards; K Mantripragada; M Owen; M C O'Donovan; M Gill; A Corvin; D W Morris; G Donohoe Journal: Transl Psychiatry Date: 2017-01-24 Impact factor: 6.222